Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESOC 2023 | Arterial cardiopathy and its role in the initiation of embolic strokes

Thomas Meinel, MD, Bern University Hospital, and University of Bern, Bern, Switzerland discusses some of the key trial readouts at ESOC 2023. Dr Meinel references the ELAN trial (NCT03148457), which revealed it beneficial to initiate anticoagulation treatments earlier in patients with atrial fibrillation-related stroke, and the ARCADIA trial (NCT03192215), which tested if anticoagulation therapy would be better than anti-platelet therapy for the prevention of recurrent stroke in subjects with cryptogenic ischemic stroke and atrial cardiopathy. While neutral, ARCADIA provided valuable insights on the embolic stroke of undetermined source (ESUS) construct and how to approach future investigations in this space. This interview took place during the European Stroke Organisation Conference (ESOC) in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Thomas Meinel reports the following disclosures: Funding from Swiss National Science Foundation, Swiss Heart Foundation, SAMW/Bangerter Rhyner Foundation, and University Bern.